Table 1 Patient demographics
Patient no., n | 63 |
|---|---|
Age, median (IQR) | 63.1 (56.0–70.5) |
Median follow up, months (IQR) | 17.5 (9.2–28.4) |
Sex, n (%) | |
Male | 52 (82.5) |
Female | 11 (17.5) |
ECOG PS, n (%) | |
0–1 | 36 (57.1) |
≥2 | 27 (42.9) |
Disease free interval, n (%) | |
<1 year | 40 (63.5) |
≥1 year | 23 (36.5) |
Lung metastasis, n (%) | |
Yes | 39 (61.9) |
No | 24 (38.1) |
Liver metastasis, n (%) | |
Yes | 6 (9.5) |
No | 57 (90.5) |
Lymph node metastasis, n (%) | |
Yes | 25 (39.7) |
No | 38 (60.3) |
Bone metastasis, n (%) | |
Yes | 19 (30.2) |
No | 44 (69.8) |
Brain metastasis, n (%) | |
Yes | 5 (7.9) |
No | 58 (92.1) |
Metastasis at other site, n (%) | |
Yes | 13 (20.6) |
No | 50 (79.4) |
Number of metastatic sites, n (%) | |
1 | 37 (54.4) |
≥2 | 31 (45.6) |
Previous nephrectomy, n (%) | |
Yes | 35 (55.6) |
No | 28 (44.4) |
TKI regimen, n (%) | |
Sunitinib | 40 (63.5) |
Pazopanib | 23 (36.5) |
Response to TKIs, n (%) | |
CR | 3 (4.8) |
PR | 12 (19.0) |
SD | 35 (55.6) |
PD | 13 (20.6) |
Neutrophil–lymphocyte ratio, n (%) | |
≤3.6 | 34 (54.0) |
>3.6 | 29 (46.0) |
Platelet–lymphocyte ratio, n (%) | |
≤150 | 37 (58.7) |
>150 | 26 (41.3) |
Hemoglobin, n (%) | |
<12 (g/dL) | 25 (39.7) |
≥12 (g/dL) | 38 (60.3) |
Corrected calcium, n (%) | |
<10 (mg/dL) | 57 (90.5) |
≥10 (mg/dL) | 6 (9.5) |
MSKCC risk | |
Favorable | 19 (30.2) |
Intermediate | 41 (65.1) |
Poor | 3 (4.8) |
Progression | 48 (76.2) |
Death | 29 (46.0) |